← all works
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Head and Neck Cancer Studies
- Field
- Medicine
- Canadian institutions
- Centre Hospitalier de l’Université de Montréal
- Funders
- National Institute for Health and Care ResearchRegeneron PharmaceuticalsEisaiSanofiAmgenPfizerAstraZenecaEli Lilly and CompanyGlaxoSmithKline
- Keywords
- CetuximabPembrolizumabMedicineChemotherapyHead and neckOncologyOpen labelInternal medicineHead and neck squamous-cell carcinomaHead and neck cancerBasal cellRadiation therapyRandomized controlled trialSurgeryCancerImmunotherapyColorectal cancer
- Has abstract in OpenAlex
- no